134 related articles for article (PubMed ID: 33531609)
1. Predictive impact of C-reactive protein to albumin ratio for recurrent or metastatic head and neck squamous cell carcinoma receiving nivolumab.
Tanoue K; Tamura S; Kusaba H; Shinohara Y; Ito M; Tsuchihashi K; Shirakawa T; Otsuka T; Ohmura H; Isobe T; Ariyama H; Koreishi S; Matsushita Y; Shimokawa H; Tanaka R; Mitsugi K; Akashi K; Baba E
Sci Rep; 2021 Feb; 11(1):2741. PubMed ID: 33531609
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Yamashita G; Okamoto I; Ito T; Tokashiki K; Okada T; Tsukahara K
Anticancer Res; 2023 Aug; 43(8):3679-3683. PubMed ID: 37500154
[TBL] [Abstract][Full Text] [Related]
3. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
4. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
[TBL] [Abstract][Full Text] [Related]
5. Post-treatment Neutrophil/Lymphocyte Ratio Is a Prognostic Factor in Head and Neck Cancers Treated With Nivolumab.
Iwasa YI; Kitoh R; Yokota Y; Hori K; Kasuga M; Kobayashi T; Kanda S; Takumi Y
Cancer Diagn Progn; 2024; 4(2):182-188. PubMed ID: 38434918
[TBL] [Abstract][Full Text] [Related]
6. Dynamic alterations of circulating T lymphocytes and the clinical response in patients with head and neck squamous cell carcinoma treated with nivolumab.
Tada H; Takahashi H; Yamada K; Masuda K; Nagata Y; Uchida M; Shino M; Ida S; Mito I; Matsuyama T; Oyama T; Tatematsu KI; Sezutsu H; Takeda S; Chikamatsu K
Cancer Immunol Immunother; 2022 Apr; 71(4):851-863. PubMed ID: 34463793
[TBL] [Abstract][Full Text] [Related]
7. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS; Cavalieri S; Licitra L; Pistore F; Lenoci D; Canevari S; Airoldi M; Cossu Rocca M; Strojan P; Kuhar CG; Merlano M; Perrone F; Vingiani A; Denaro N; Perri F; Argiris A; Gurizzan C; Ghi MG; Cassano A; Allegrini G; Bossi P; De Cecco L
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290766
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory prognostic factors in advanced or recurrent esophageal squamous cell carcinoma treated with nivolumab.
Ikoma T; Shimokawa M; Matsumoto T; Boku S; Yasuda T; Shibata N; Kurioka Y; Takatani M; Nobuhisa T; Namikawa T; Kitagawa H; Hanazaki K; Doi K; Shimada T; Tsumura T; Marusawa H; Kanaya S; Morita S; Inokuma T; Nagai H; Yasui H; Satake H
Cancer Immunol Immunother; 2023 Feb; 72(2):427-435. PubMed ID: 35927359
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint blockade induced shifts in cytokine expression patterns in peripheral blood of head and neck cancer patients are linked to outcome.
Röhl L; Wellhausen J; Berszin M; Krücken I; Zebralla V; Pirlich M; Wiegand S; Dietz A; Wald T; Wichmann G
Front Immunol; 2023; 14():1237623. PubMed ID: 37849764
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre's Real-World Experience.
Du YJ; Fu R; Levinsky JT; Kamalraj P; Chan KKW; Parmar A; Eskander A; Smoragiewicz M
Curr Oncol; 2023 Sep; 30(10):8928-8935. PubMed ID: 37887545
[TBL] [Abstract][Full Text] [Related]
11. Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer.
Cabezas-Camarero S; Iglesias-Moreno MC; Cerezo Druet E; Sotelo MJ; Merino-Menéndez S; Cabrera-Martín MN; Plaza-Hernández JC; Pérez-Segura P
Anticancer Drugs; 2023 Jun; 34(5):695-698. PubMed ID: 36730545
[TBL] [Abstract][Full Text] [Related]
12. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Jayaprakash V; Wei L; Ferris RL
Oncologist; 2022 Mar; 27(2):e194-e198. PubMed ID: 35641218
[TBL] [Abstract][Full Text] [Related]
13. Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.
Yamakawa N; Umeda M; Yoshii Y; Mitsudo K; Noguchi M; Kusukawa J; Katakura A; Nakayama H; Sasaki M; Noguchi T; Ueda M; Bukawa H; Yagihara K; Horie A; Miyazaki A; Chikazu D; Tomihara K; Mishima K; Otsuru M; Asoda S; Fujiwara S; Ohyama Y; Kurita H; Kawamata H; Fukuda M; Shintani Y; Kobayashi T; Kanno T; Oh-Iwa I; Kawano K; Yamashita Y; Kobayashi W; Ohiro Y; Uzawa K; Ota Y; Kirita T
Oral Dis; 2024 Mar; 30(2):247-258. PubMed ID: 36519515
[TBL] [Abstract][Full Text] [Related]
14. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.
Nenclares P; Gunn L; Soliman H; Bover M; Trinh A; Leslie I; Wong KH; Melcher A; Newbold K; Nutting CM; Ap Dafydd D; Bhide SA; Harrington K
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103355
[TBL] [Abstract][Full Text] [Related]
15. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab.
Suzuki S; Taguchi Y; Kitabayashi T; Sato N; Kaya H; Abe T; Endo T; Suzuki H; Kawasaki Y; Yamada T
J Clin Med; 2024 Apr; 13(9):. PubMed ID: 38730986
[No Abstract] [Full Text] [Related]
16. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Ding Q; Liu Y; Ju H; Song H; Xiao Y; Liu X; Ren G; Wei D
Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e525-e529. PubMed ID: 37330963
[TBL] [Abstract][Full Text] [Related]
17. T cell repertoire in peripheral blood as a potential biomarker for predicting response to concurrent cetuximab and nivolumab in head and neck squamous cell carcinoma.
Wang X; Muzaffar J; Kirtane K; Song F; Johnson M; Schell MJ; Li J; Yoder SJ; Conejo-Garcia JR; Guevara-Patino JA; Bonomi M; Bhateja P; Rocco JW; Steuer CE; Saba NF; Chung CH
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35676062
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada.
Zereshkian A; Shafi R; Pond GR; Hotte SJ
J Immunother; 2024 May; 47(4):123-127. PubMed ID: 38230590
[TBL] [Abstract][Full Text] [Related]
19. Utility of palliative prognostic index and neutrophil-to-lymphocyte ratio in predicting prognosis of end-stage squamous cell carcinoma of head and neck.
Higashino M; Sugimoto K; Onishi S; Okabe K; Yasuda C; Tadokoro H; Kawata R
Head Neck; 2024 Jan; 46(1):23-28. PubMed ID: 37850401
[TBL] [Abstract][Full Text] [Related]
20. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma.
Ueta R; Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Ouchi K; Kasahara Y; Taniguchi S; Yoshida Y; Sasaki K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(3):252-259. PubMed ID: 37708868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
